| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.
|
Blood
|
2011
|
4.03
|
|
2
|
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
|
Blood
|
2004
|
2.83
|
|
3
|
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.
|
JAMA
|
2004
|
2.65
|
|
4
|
Survival after recurrence of Ewing's sarcoma family of tumors.
|
J Clin Oncol
|
2005
|
2.33
|
|
5
|
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
2.32
|
|
6
|
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
|
Blood
|
2002
|
2.12
|
|
7
|
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.
|
J Clin Oncol
|
2010
|
1.84
|
|
8
|
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
|
Blood
|
2002
|
1.80
|
|
9
|
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
|
Blood
|
2003
|
1.72
|
|
10
|
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.
|
Blood
|
2007
|
1.72
|
|
11
|
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
|
Blood
|
2006
|
1.65
|
|
12
|
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
|
Blood
|
2007
|
1.52
|
|
13
|
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.
|
Biol Blood Marrow Transplant
|
2009
|
1.46
|
|
14
|
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up.
|
Br J Haematol
|
2005
|
1.35
|
|
15
|
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party.
|
Blood
|
2007
|
1.22
|
|
16
|
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2010
|
1.13
|
|
17
|
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
1.12
|
|
18
|
Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias.
|
Biol Blood Marrow Transplant
|
2002
|
1.11
|
|
19
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
|
Biol Blood Marrow Transplant
|
2007
|
1.10
|
|
20
|
Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.
|
J Pediatr Hematol Oncol
|
2004
|
1.09
|
|
21
|
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2008
|
1.05
|
|
22
|
Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.
|
Biol Blood Marrow Transplant
|
2009
|
1.04
|
|
23
|
Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation.
|
Biol Blood Marrow Transplant
|
2010
|
1.03
|
|
24
|
HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.
|
Biol Blood Marrow Transplant
|
2007
|
1.02
|
|
25
|
Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2007
|
1.02
|
|
26
|
Hypertension in long-term survivors of pediatric hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.01
|
|
27
|
National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.
|
Biol Blood Marrow Transplant
|
2012
|
1.01
|
|
28
|
Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation.
|
Pediatr Blood Cancer
|
2006
|
0.98
|
|
29
|
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children.
|
Blood
|
2002
|
0.98
|
|
30
|
NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.
|
Biol Blood Marrow Transplant
|
2011
|
0.96
|
|
31
|
Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years.
|
Blood
|
2007
|
0.96
|
|
32
|
Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2003
|
0.96
|
|
33
|
Diagnosis and clinical management of chronic graft-versus-host disease.
|
Int J Hematol
|
2004
|
0.95
|
|
34
|
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2002
|
0.91
|
|
35
|
Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
|
Biol Blood Marrow Transplant
|
2011
|
0.91
|
|
36
|
Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia.
|
Br J Haematol
|
2002
|
0.90
|
|
37
|
Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure?
|
Biol Blood Marrow Transplant
|
2002
|
0.90
|
|
38
|
Steroid-refractory graft-vs.-host disease: past, present and future.
|
Pediatr Transplant
|
2003
|
0.87
|
|
39
|
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.86
|
|
40
|
Success of allogeneic marrow transplantation for children with severe aplastic anaemia.
|
Br J Haematol
|
2012
|
0.85
|
|
41
|
BK nephropathy in pediatric hematopoietic stem cell transplant recipients.
|
Pediatr Transplant
|
2008
|
0.85
|
|
42
|
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
|
Cancer
|
2002
|
0.84
|
|
43
|
NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions.
|
Biol Blood Marrow Transplant
|
2011
|
0.83
|
|
44
|
Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
|
Cancer
|
2004
|
0.82
|
|
45
|
Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.
|
Biol Blood Marrow Transplant
|
2010
|
0.80
|
|
46
|
A simulation-based comparison of two methods for determining relaxation rates from relaxometry images.
|
Magn Reson Imaging
|
2011
|
0.77
|
|
47
|
Late effects following hematopoietic cell transplantation for children.
|
Biol Blood Marrow Transplant
|
2008
|
0.77
|